Patents Issued in May 20, 2021
-
Publication number: 20210145949Abstract: The methods include selectively reducing or expanding T cells according to the antigenic specificity of the T cells. Therefore, the present invention can be used to reduce or eliminate pathogenic T cells that recognize autoantigens, such as beta cell specific T cells. As such, the present invention can be used to prevent, treat or ameliorate autoimmune diseases such as IDDM. Furthermore, the present invention can be used to expand desirable T cells, such as anti-pathogenic T cells to prevent, treat and/or ameliorate autoimmune diseases.Type: ApplicationFiled: November 13, 2020Publication date: May 20, 2021Inventors: Pedro SANTAMARIA, Anna MOORE
-
Publication number: 20210145950Abstract: The present application relates to arenaviruses with rearrangements of their open reading frames (“ORF”) in their genomes. In particular, described herein is a modified arenavirus genomic segment, wherein the arenavirus genomic segment is engineered to carry a viral ORF in a position other than the wild-type position of the ORF. Also described herein are trisegmented arenavirus particles comprising one L segment and two S segments or two L segments and one S segment. The arenavirus, described herein may be suitable for vaccines and/or treatment of diseases and/or for the use in immunotherapies.Type: ApplicationFiled: July 7, 2020Publication date: May 20, 2021Inventors: Daniel David Pinschewer, Doron Merkler, Sandra Margarete Kallert, Mario Kreutzfeldt, Stéphanie Gabrielle Darbre Abdelrahman, Nicolas Jean Page
-
Publication number: 20210145951Abstract: The present invention relates to improved strategies, compositions, and methods for producing shared neoplasia vaccines, including “off the shelf” pre-furnished shared neo-epitope warehouses, which can be used to enable the rapid production of bladder cancer neoantigen-based vaccines. The present invention relates to identified and designed shared neo-epitopes based on non-synonymous mutations that are present in at least 1% of subjects having bladder cancer. The strategies, compositions, and methods include the identification of neo-epitopes that are known or determined (e.g. predicted) to engage regulatory T cells and/or other detrimental T cells (including T cells with potential host cross-reactivity and/or anergic T cells) and exclusion of such identified neo-epitopes that are known or determined (e.g.Type: ApplicationFiled: November 18, 2020Publication date: May 20, 2021Inventors: William D. Martin, Anne S. De Groot, Gad Berdugo, Guilhem Richard, Dominique Bridon, Leonard Moise, Michael F. Princiotta
-
Publication number: 20210145952Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.Type: ApplicationFiled: January 15, 2021Publication date: May 20, 2021Inventors: Andrea MAHR, Toni WEINSCHENK, Oliver SCHOOR, Jens FRITSCHE, Harpreet SINGH, Claudia WAGNER, Julia LEIBOLD, Colette SONG
-
Publication number: 20210145953Abstract: Disclosed are an attenuation system and the use thereof for attenuating plasmodia, specifically the use of an EF1g gene for attenuating plasmodia. The attenuation system regulates the expression or degradation of the EF1g gene by using a regulatory system, thereby controlling the growth of plasmodia and achieving the attenuation of plasmodia.Type: ApplicationFiled: April 26, 2018Publication date: May 20, 2021Applicant: GUANGZHOU CAS LAMVAC BIOTECH CO., LTDInventors: Xingxiang Liang, Jianhua Su, Meiling Wang, Ying Tong, Yongchao Yao, Li Qin, Xiaoping Chen
-
Publication number: 20210145954Abstract: The present invention relates to Salmonella mutant strains and their use as a vaccine for preventing Salmonella infection, in particular in eggs.Type: ApplicationFiled: October 14, 2020Publication date: May 20, 2021Applicant: Universiteit GentInventors: Filip Van Immerseel, Ruth Raspoet, Richard Ducatelle
-
Publication number: 20210145955Abstract: Disclosed herein are compositions and methods for use in neurotoxin treatments.Type: ApplicationFiled: June 26, 2018Publication date: May 20, 2021Inventors: Kenton Abel, Michael Jarpe, Fauad Hasan
-
Publication number: 20210145956Abstract: This disclosure relates to methods for eliciting an immune response against C. difficile toxin A and toxin B in an adult human subject. The subject may be at risk for a primary symptomatic C. difficile infection. In some embodiments, a method is for eliciting an immune response against C. difficile toxin A and toxin B in an adult human subject at risk for a primary symptomatic C. difficile infection, and comprises administering to the subject a composition comprising C. difficile toxoid A and toxoid B at least three times, each administration being about seven days apart.Type: ApplicationFiled: January 8, 2021Publication date: May 20, 2021Applicant: Sanofi Pasteur, Inc.Inventors: Patricia Pietrobon, Ginamarie Foglia, Guy De Bruyn, Sanjay Gurunathan
-
Publication number: 20210145957Abstract: The invention relates to immunogenic polysaccharide-protein conjugates comprising a capsular polysaccharide (CP) from Streptococcus agalactiae, commonly referred to as group B. streptococcus (GBS), and a carrier protein, wherein the CP is selected from the group consisting of serotypes Ia, Ib, II, III, IV, V, VI, VII, VIII, and IX, and wherein the CP has a sialic acid level of greater than about 60%. The invention also relates to methods of making the conjugates and immunogenic compositions comprising the conjugates. The invention also relates to immunogenic compositions comprising polysaccharide-protein conjugates, wherein the conjugates comprise a CP from GBS serotype IV and at least one additional serotype. The invention further relates to methods for inducing an immune response in subjects against GBS and/or for reducing or preventing invasive GBS disease in subjects using the compositions disclosed herein. The resulting antibodies can be used to treat or prevent GBS infection via passive immunotherapy.Type: ApplicationFiled: January 28, 2021Publication date: May 20, 2021Applicant: Pfizer Inc.Inventors: Annaliesa Sybil Anderson, Amardeep Singh Bhupender Bhalla, Robert G.K. Donald, Jianxin Gu, Kathrin Ute Jansen, Rajesh Kumar Kainthan, Lakshmi Khandke, Jin-Hwan Kim, Paul Liberator, Avvari Krishna Prasad, Mark Edward Ruppen, Ingrid Lea Scully, Suddham Singh, Cindy Xudong Yang
-
Publication number: 20210145958Abstract: Recombinant chimeric bovine/human parainfluenza virus 3 (rB/HPIV3) vectors expressing Respiratory Syncytial Virus (RSV) G protein or a recombinant RSV G protein, as well as methods of their use and manufacture, are provided. The rB/HPIV3 vector comprises a genome comprising a heterologous gene encoding the RSV G protein or the recombinant RSV G protein. Nucleic acid molecules comprising the sequence of the genome or antigenome of the disclosed rB/HPIV3 vectors are also provided. The disclosed rB/HPIV3 vectors can be used, for example, to induce an immune response to RSV and HPIV3 in a subject.Type: ApplicationFiled: May 29, 2018Publication date: May 20, 2021Applicant: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICESInventors: Peter L. Collins, Ursula J. Buchholz, Bo Liang, Shirin Munir
-
Publication number: 20210145959Abstract: The present disclosure is directed towards chimeric glycoproteins wherein the clip region, a core region, a flap region, and a transmembrane and cytoplasmic domain are defined by starting from the amino terminus of the protein, these domains are comprised of the following amino acid residue ranges: clip, 1 through 40 to 60; core, 40 to 60 through 249 to 281; flap, 249 to 281 through 419 to 459; the transmembrane domain is comprised of amino acids 460 through 480, and the remaining amino acids 481 through 525 comprise the cytoplasmic domain; and wherein the clip, core, flap, transmembrane, and cytoplasmic domain comprise a chimeric combination of at least two lyssavirus, wherein the chimeric glycoprotein is advantageously inserted into a rabies-based vaccine vector.Type: ApplicationFiled: June 13, 2018Publication date: May 20, 2021Applicants: Thomas Jefferson University, ICAHN School of Medicine at Mount SinaiInventors: Schnell Matthias, Christine Rettew Fisher, Christoph Wirblich, Gene Tan
-
Publication number: 20210145960Abstract: An experiment has shown that ranpirnase is a microbicide. It is believed that topical application of a topical pharmaceutical composition consisting essentially of a prophylactically effective concentration of an enzymatically-active ribonuclease (e.g. ranpirnase) and a viscous vehicle that does not unacceptably interfere with the enzymatic activity (e.g. K-Y® Brand Jelly) will prophylactically protect an individual from a sexually-transmitted viral infection, particularly HIV. It is also believed that e.g. ranpirnase can be delivered to tissues of an individual who is to be prophylactically protected against viral infections by transfecting ranpirnase DNA into human microbiota and exposing the individual to the thus-modified human microbiota. It is also believed that ranpirnase can be delivered to a woman who is to be prophylactically protected against a sexually-transmitted viral infection by use of an intravaginal ring that has been impregnated with ranpirnase.Type: ApplicationFiled: October 6, 2020Publication date: May 20, 2021Applicant: ORGENESIS INC.Inventors: Jamie SULLEY, Luis SQUlQUERA, David SIDRANSKY, Tom HODGE
-
Publication number: 20210145961Abstract: The present invention relates to immunogenic therapies for the treatment or prevention of a human immunodeficiency virus (HIV) infection or a disease associated with an HIV infection.Type: ApplicationFiled: November 12, 2020Publication date: May 20, 2021Inventors: Christian BRANDER, Beatriz MOTHE-PUJADAS
-
Publication number: 20210145962Abstract: A method is presented for treating herpes simplex virus (HSV) infection comprising: (a) locally administering a substance that induces a delayed type hypersensitivity (DTH) response to a patient at a site of an HSV lesion to induce a DTH response at the site of the lesion during one or more outbreaks of the HSV infection.Type: ApplicationFiled: January 28, 2021Publication date: May 20, 2021Inventor: Hugh McTavish
-
Publication number: 20210145963Abstract: The present disclosure provides immunogenic compositions comprising HCV E1, E2, or E1/E2 polypeptides from two or more different HCV genotypes. The present disclosure provides immunogenic compositions comprising HCV E2 or E1/E2 polypeptides from two or more different HCV genotypes. The immunogenic compositions are useful in carrying out methods of inducing an immune response to HCV. The present disclosure further provides methods of stimulating an immune response to HCV in an individual.Type: ApplicationFiled: May 15, 2014Publication date: May 20, 2021Inventors: Michael Houghton, Darren Hockman, John L. Law, Michael Logan, D. Lorne Tyrrell
-
Publication number: 20210145964Abstract: The invention relates to a method for treating a human patient having a cancer characterized by at least one stroma-rich tumor, said human patient having increased disintegrin and metalloproteinase domain-containing protein 12 (ADAM12) levels in a bodily fluid, when compared to ADAM12 levels in a bodily fluid of a control person, the method comprising treating the human patient with a stroma-targeting agent. The invention further relates to a composition comprising a stroma-targeting agent for treating a human patient diagnosed with cancer characterized with at least one stroma-rich tumor, and one or more pharmaceutically acceptable excipients.Type: ApplicationFiled: November 15, 2019Publication date: May 20, 2021Inventors: Maarten Fokke BIJLSMA, Hanneke Wilma Marlies VAN LAARHOVEN
-
Publication number: 20210145965Abstract: Disclosed are methods for treating cancer in a subject in need thereof. The methods comprise administering to the subject an inhibitor of a checkpoint kinase and administering to the subject immunotherapy.Type: ApplicationFiled: November 18, 2020Publication date: May 20, 2021Inventors: Crismita C. Dmello, Adam M. Sonabend Worthalter, Catalina Lee Chang, Li Chen
-
Publication number: 20210145966Abstract: Improved anti-CD154 antibodies are provided herein which have improved therapeutic potency, in vivo half-life and ablated FcR binding and/or complement binding/activation. The use of these antibodies for inducing tolerance and treating immune diseases including autoimmunity, inflammation, transplant recipients, fibrosis and allergic disorders is disclosed herein.Type: ApplicationFiled: November 23, 2020Publication date: May 20, 2021Inventors: Jay Rothstein, Robert George Edward Holgate, Arron Hearn
-
Publication number: 20210145967Abstract: The present disclosure generally relates to magnetic liquid particles, and methods for using the magnetic liquid particles. More specifically, the present disclosure relates to magnetic liquid particles having antimicrobial properties. The particles can comprise a liquid metal core comprising a liquid gallium or alloy thereof, and a plurality of magnetic iron particles; and an inorganic passivation layer encapsulating the liquid metal core. The particles can be used for disrupting a biofilm. The particles can also be used for the treatment of biofilm related diseases.Type: ApplicationFiled: November 14, 2019Publication date: May 20, 2021Inventors: James Chapman, Vi Khanh Truong, Samuel Cheeseman, Torben Jost Daeneke, Aaron James Elbourne
-
Publication number: 20210145968Abstract: The present invention discloses a hypocrellin derivative substituted both in a peri-position and in a 2-position by an amino, and a preparation method and use thereof. A general structural formula of the derivative is as represented by formulas I-a to I-d: The hypocrellin derivative substituted both in a peri-position and in a 2-position by an amino prepared in the present invention has a maximum absorption wavelength of 600-650 nm and a molar extinction coefficient reaching about 20000-40000 M?1cm?1. Compared with unmodified hypocrellin or hypocrellin having only a 2-position modified, an absorption spectrum of the derivative is significantly red-shifted and the molar extinction coefficient is greatly improved, and the derivative can efficiently produce reactive oxygen species such as singlet oxygen in a photosensitive condition.Type: ApplicationFiled: September 5, 2018Publication date: May 20, 2021Applicant: TECHNICAL INSTITUTE OF PHYSICS AND CHEMISTRY OF THE CHINESE ACADEMY OF SCIENCESInventors: Pengfei WANG, Jiasheng WU, Weimin LIU, Xiuli ZHENG, Ying GU
-
Publication number: 20210145969Abstract: The invention relates to a dissolution chamber (10) for use with a catheter for dissolving and preparing an aqueous solution of a water-soluble photosensitizing agent for installation into the bladder, e.g. for use in photodynamic diagnosis (PDD) or photodynamic therapy (PDT) of bladder cancer and to a method for preparing a liquid pharmaceutical preparation for delivery into a patient's bladder which includes the use of said dissolution chamber (10).Type: ApplicationFiled: June 21, 2018Publication date: May 20, 2021Inventor: Tore Gjørsvik
-
Publication number: 20210145970Abstract: A stimulus-responsive micellar carrier, methods that may be associated with making a stimulus-responsive micellar carrier, and methods that may be associated with using a stimulus-responsive micellar carrier are disclosed. The stimulus-responsive micellar carrier comprises a cargo molecule, and a linear block copolymer having a hydrophilic block connected to a hydrophobic block by a stimulus-responsive junction moiety. The micellar carrier can be supplied to a patient body for therapeutic purposes, such as the treatment of cancerous tissue. A method of preparing or obtaining a stimulus-responsive micellar carrier may include preparing a polyethylene glycol material having an acetal end group and then preparing a block copolymer by forming a reaction mixture including the polyethylene glycol material, a cyclic carbonate monomer, and a base.Type: ApplicationFiled: December 22, 2020Publication date: May 20, 2021Inventors: Dylan J. BODAY, Jeannette M. GARCIA, James L. HEDRICK, Nathaniel PARK, Rudy J. WOJTECKI, Yang CHUAN, Ashlynn LEE, Zhen Chang LIANG, Shaoqiong LIU, Yi Yan YANG
-
Publication number: 20210145971Abstract: Conjugates of an active agent attached to a targeting moiety, such as at least one HSP90 binding moiety, via a linker, have been designed. Such conjugates can provide improved temporospatial delivery of the active agent, improved biodistribution and penetration in tumor, and/or decreased toxicity. Methods of making the conjugates and the formulations thereof are provided. Methods of administering the formulations to a subject in need thereof are provided, for example, to treat or prevent cancer.Type: ApplicationFiled: April 3, 2019Publication date: May 20, 2021Inventors: Mark T. Bilodeau, Benoît Moreau, Sudhakar Kadiyala, Richard Wooster, Brian H. White
-
Publication number: 20210145972Abstract: The present invention relates to a nanostructure comprising: a) a nucleic acid scaffold; and b) at least two peptide moieties, wherein the at least two peptide moieties specifically bind to a molecule expressed on the surface of a virus and are attached to the nucleic acid scaffold, wherein the structure of the nucleic acid scaffold is selected from the group of: i) a linear nucleic acid scaffold, wherein the at least two peptide moieties are each attached at or near different ends of the nucleic acid scaffold; and ii) a branched nucleic acid scaffold, wherein the at least two peptide moieties are each attached to a different branch of the scaffold. The invention furthermore relates to the nanostructure of the invention for use as a medicament, and more specifically for use in the treatment of viral infections. The invention also relates to the nanostructure of the invention for the use in diagnostic purposes and in methods of detecting whether a virus is present in a sample.Type: ApplicationFiled: May 25, 2018Publication date: May 20, 2021Inventors: David Michael Smith, Jessica Sophie Lorenz, Christin Möser, Jasmin Fertey, Walter Stöcklein, Andreas Herrmann, Daniel Lauster
-
Publication number: 20210145973Abstract: Provided herein are, inter alia, nucleic acid-peptide conjugates including a non-cell penetrating protein attached at its C-terminus to a phosphorothioate nucleic acid. Attachment of the phosphorothioate nucleic acid to the non-cell penetrating protein conveys stability to and allows for efficient intracellular delivery of the non-cell penetrating peptide. The nucleic acid-peptide conjugates provided herein including embodiments thereof are useful, inter alia, for the treatment of cancer, inflammatory disease, pain, and viral infection.Type: ApplicationFiled: July 13, 2018Publication date: May 20, 2021Inventors: Andreas HERRMANN, Hua YU, Toshikage NAGAO
-
Publication number: 20210145974Abstract: The present invention is directed to bifunctional small molecules which contain a circulating protein binding moiety (CPBM) linked through a linker group to a cellular receptor binding moiety (CRBM) which is a membrane receptor of degrading cell such as a hepatocyte or other degrading cell. In embodiments, the (CRBM) is a moiety which binds to asialoglycoprotein receptor (an asialoglycoprotein receptor binding moiety, or ASGPRBM) of a hepatocyte. In additional embodiments, the (CRBM) is a moiety which binds to a receptor of other cells which can degrade proteins, such as a LRP1, LDLR, Fc?RI, FcRN, Transferrin or Macrophage Scavenger receptor. Pharmaceutical compositions based upon these bifunctional small molecules represent an additional aspect of the present invention. These compounds and/or compositions may be used to treat disease states and conditions by removing circulating proteins through degradation in the hepatocytes or macrophages of a patient or subject in need of therapy.Type: ApplicationFiled: April 8, 2019Publication date: May 20, 2021Inventors: David Spiegel, David Caianiello, Mengwen Zhang
-
Publication number: 20210145975Abstract: The present application relates to an immunostimulatory compound comprising an immunostimulant portion and a peptide portion. The peptide portion is not a disease-associated immunogen. Furthermore, the peptide portion has an amino acid sequence in which 75% or less of the amino acid residues are hydrophobic and/or has an isoelectric point of 5 or greater. The compounds of the invention address the problem of systemic distribution of immunostimulants causing unwanted side effects. The inventors have found that the physicochemical properties of the immunostimulant can be controlled by covalent linkage to a peptide. Further physicochemical properties may be modified in a useful manner by incorporating additional features.Type: ApplicationFiled: November 6, 2020Publication date: May 20, 2021Inventor: Bertrand GEORGES
-
Publication number: 20210145976Abstract: The present disclosure relates to polypeptides, such as fibronectin type III (FN3) domains that can bind CD71, their conjugates, isolated nucleotides encoding the molecules, vectors, host-cells, as well as methods of making and using the same.Type: ApplicationFiled: October 14, 2020Publication date: May 20, 2021Inventors: Russell C. Addis, Zhanna Druzina, Robert Kolakowski, Swapnil Kulkarni, Steven G. Nadler, Karyn O'Neil, Yao Xin
-
Publication number: 20210145977Abstract: The present invention relates to methods and pharmaceutical composition for the treatment of cancer. In particular, the present invention relates to a method for enhancing the potency of an immune checkpoint inhibitor administered to a subject as part of a treatment regimen for cancer, the method comprising: administering a pharmaceutically effective amount of a TNF? blocking agent to a subject in combination with the immune checkpoint inhibitor.Type: ApplicationFiled: January 12, 2021Publication date: May 20, 2021Inventors: Thierry LEVADE, Bruno SEGUI, Nicolas MEYER, Céline COLACIOS VIATGÉ, Nathalie ANDRIEU-ABADIE, Florie BERTRAND
-
Publication number: 20210145978Abstract: The invention relates generally to conjugated activatable antibodies that bind CD71 in their active form and methods of making and using these anti-CD71 conjugated activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.Type: ApplicationFiled: November 25, 2020Publication date: May 20, 2021Inventors: Shweta Singh, Jennifer Hope Richardson, Laura Patterson Serwer, Jonathan Alexander Terret, Susan E. Morgan-Lappe, Tracy Henriques, Sherry L. Ralston, Marvin Robert Leanna, Ilari Badagnani, Sahana Bose
-
Publication number: 20210145979Abstract: Antibody drug conjugates (ADC's) that bind to CD37 protein and variants thereof are described herein. CD37 exhibits a distinct and limited expression pattern in normal adult tissue(s), and is aberrantly expressed in the cancers listed in Table I. Consequently, the ADC's of the invention in some embodiments provide a therapeutic composition for the treatment of cancer.Type: ApplicationFiled: April 17, 2020Publication date: May 20, 2021Applicant: AGENSYS, INC.Inventors: Daniel Sousa PEREIRA, Faisal Hayat MALIK, Josh SNYDER, Leslie Renee BUTTERWORTH, Ssucheng Jeff HSU, Peng YANG, Claudia Isabel GUEVARA
-
Publication number: 20210145980Abstract: The present invention provides a biomatrix layer comprising, consisting essentially of or consisting of a sulfated oligosaccharide at a concentration in the range of 0.1 ?M to 1,000 ?M and a peptide-polyethylene glycol-conjugate according to formula (I): PEG-R1-(BX)n (I) wherein B is lysine or arginine, X is selected from alanine, glycine, serine, threonine, tyrosine, glutamic acid or aspartic acid and n is an integer selected from 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 and 20; R1 may be absent or is a peptide comprising 5 to 30 amino acids; PEG is comprised at a concentration in the range of 0.1 ?M to 1,000 ?M; R1, if present, is comprised at a concentration in the range of 0.1 ?M to 4,000 ?M; (BX)n is comprised at a concentration in the range of 0.25 ?M to 1,000 ?M. The invention further relates to processes for assembling the biomatrix layer.Type: ApplicationFiled: June 18, 2018Publication date: May 20, 2021Applicant: DENOVOMATRIX GMBHInventors: Yixin ZHANG, Alvin THOMAS, Richard WETZEL, Dejan HUSMAN, Robert WIEDUWILD
-
Publication number: 20210145981Abstract: A method of killing cells of a targeted cell type in a patient body that utilizes nanoparticles having a first portion, which when exposed to a target portion of a targeted cell type, binds to the target portion and a second portion, joined to the first portion, and comprised of a low resistivity material. The nanoparticles are introduced into a contact area where they contact cells of the targeted cell type. Contemporaneously, the contact area is exposed to a varying magnetic field of insufficient strength to increase the temperature of any part of the patient body by more than ten degrees Celsius, but which creates a current at the nanoparticles sufficient to disrupt function of the targeted cell type.Type: ApplicationFiled: January 4, 2021Publication date: May 20, 2021Inventor: ROBERT E. SANDSTROM
-
Publication number: 20210145982Abstract: This disclosure provides improved lipid-based compositions, including lipid nanoparticle compositions, and methods of use thereof for delivering agents in vivo including nucleic acids and proteins.Type: ApplicationFiled: June 15, 2018Publication date: May 20, 2021Applicant: ModernaTX, Inc.Inventors: Stephen Hoge, Joseph Schariter, Charles Bowerman, Michael H. Smith, Yan Xia
-
Publication number: 20210145983Abstract: In one aspect, the disclosure relates to methods of treating a disease or condition characterized by allergic inflammation, including, but not limited to, asthma, allergic conjunctivitis, allergic dermatitis, allergic esophagitis, allergic rhinitis, allergen-specific serum IgE production, allergic lung and airway inflammation and airway hyper-responsiveness (AHR) with minimal pulmonary adverse reaction, by administration of at least one CSF1R inhibitor and optionally a further therapeutic agent that is an anti-inflammatory drug and/or respiratory drug. In some aspects, the disclosed CSF1R inhibitors useful in the treatment of characterized by allergic inflammation can be administered using a disclosed pharmaceutical composition. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.Type: ApplicationFiled: April 18, 2019Publication date: May 20, 2021Inventors: Gye Young Park, Hyung-Geun Moon
-
Publication number: 20210145984Abstract: A composition comprising a bioresponsive (e.g., reactive oxygen species (ROS)-responsive), antibiotic- and/or absorbent-loaded polymeric network is described. In some cases, the composition can release the antibiotic loaded therein in response to ROS or another stimulus related to inflammation. Microneedles, microneedle arrays, and skin patches comprising the composition are also described, as well as methods of treating acne or other inflammatory/infectious skin conditions.Type: ApplicationFiled: April 11, 2019Publication date: May 20, 2021Applicant: North Carolina State UniversityInventors: Zhen Gu, Yuqi Zhang
-
Publication number: 20210145985Abstract: Described herein are systems and methods for intracellular imaging, assessment, and/or treatment of tissue before, during, and/or after surgical procedures using nanoparticles (e.g., less than 50 nanometers in diameter, e.g., photoswitchable nanoparticles) and/or a super-resolution microscope system. The present disclosure describes nanoparticles (e.g., nanosensors and photoswitchable nanoparticles) that are used to monitor and/or track changes in environmental conditions and/or analytes in the cellular microenvironment before, during, and/or after surgical procedures. The present disclosure also describes systems and methods that provide information related to the distribution and/or delivery of photoswitchable nanoparticles at super resolution (e.g., using super-resolution microscopy).Type: ApplicationFiled: June 22, 2018Publication date: May 20, 2021Applicants: Memorial Sloan Kettering Cancer Center, Cornell UniversityInventors: Michelle S. Bradbury, Ulrich Wiesner, Michael Overholtzer, Nadeem R. Abu-Rustum, Brian Madajewski
-
Publication number: 20210145986Abstract: The invention pertains to an echolucent image enhancing hydrophobic, water-immiscible composition, wherein the composition turns echogenic when foamed with air or gas bubbles formed from mechanically inserting (i) air or gas; or (ii) aqueous solution with air or gas into the hydrophobic, water-immiscible composition. The invention also pertains to a foamed echogenic image enhancing hydrophobic, water-immiscible composition and optionally comprising aqueous solution forming a single-phase, said composition comprising air or gas bubbles retained in the composition, and wherein the volume ratio of aqueous solution:hydrophobic, water-immiscible composition is preferably in the range of between 0:100 (i.e. no aqueous solution) and 75:25, preferably between 0:100 and 60:40.Type: ApplicationFiled: June 27, 2018Publication date: May 20, 2021Applicant: Giskit B.V.Inventor: Johannes Franciscus Marinus Remmerswaal
-
Publication number: 20210145987Abstract: The present invention relates to a stable pharmaceutical composition of tetrofosmin or pharmaceutically acceptable salts thereof. It also relates to a lyophilized non-radioactive kit which upon reconstitution with 99mTc-pertechnetate solution gives a stable 99mTc-tetrofosmin radiopharmaceutical composition. It also provides process for the preparation of said radiopharmaceutical compositions and their use in diagnostic imaging procedures. The compositions provide desirable technical attributes such as stability, high radiochemical purity (RCP) and desired bio-distribution.Type: ApplicationFiled: November 22, 2018Publication date: May 20, 2021Applicant: Jubilant Generics LimitedInventors: Umamaheshwar M. Prasad, Harmik Sohi, Rahul Hasija, Dinesh Kumar, Kamal S. Mehta, Raj Vijaya Kuniyil Kulangara, Ashutosh Agarwal, Dharam Vir
-
Publication number: 20210145988Abstract: The present disclosure provides compositions and methods for the detection and treatment of cancer. Specifically, the compositions of the present technology include novel DOTA-haptens that may be complexed with a radioisotope (e.g., 225Ac). Also disclosed herein are methods of the using the DOTA-haptens of the present technology in diagnostic imaging as well as pretargeted radioimmunotherapy.Type: ApplicationFiled: July 5, 2018Publication date: May 20, 2021Applicant: MEMORIAL SLOAN KETTERING CANCER CENTERInventors: Sarah M. CHEAL, Michael MCDEVITT, Ouathek OUERFELLI, Steven M. LARSON, Guangbin YANG
-
Publication number: 20210145989Abstract: Disclosed is a method for increase target specificity of a mannosylated dextran therapeutic or diagnostic compound by administering at least a blocking composition comprising a backbone and one or more CD206 targeting moieties attached thereto; administering an effective amount of the mannosylated dextran therapeutic or diagnostic compound comprising a dextran backbone and one or more CD206 targeting moieties and one or more therapeutic agents attached thereto. In exemplary implementations, the molecular mass of the blocking composition backbone is at least about two times larger than the molecular mass of the mannosylated dextran backbone compound.Type: ApplicationFiled: September 30, 2020Publication date: May 20, 2021Inventors: David A. Ralph, Jeffery Arnold
-
Publication number: 20210145990Abstract: A gastrin analogue shows high uptake in CCK-2 receptor positive tumors and simultaneously a very low accumulation in the kidneys. This is achieved by a mini-gastrin analogue PP-F11 having the formula: PP-F11-X-DGlu-DGlu-DGlu-DGlu-DGlu-DGlu-Ala-Tyr-Gly-Trp-Y-Asp-Phe-NH2, wherein Y is an amino acid replacing methionine and X is a chemical group attached to the peptide for diagnostic and/or therapeutic intervention at CCK-2 receptor relevant diseases. Very suitable compounds with respect to a high tumor to kidney ratio are mini-gastrin analogues with six D-glutamic acids or six glutamines. These compounds still possess a methionine which can be oxidized easily which is a disadvantage for clinical application under GMP due to the forms which may occur. The elimination of the methionine leads to a lower affinity to oxidation which in general favors the tumor-kidney-ratio. Ideally, the methionine is replaced by norleucine.Type: ApplicationFiled: December 18, 2020Publication date: May 20, 2021Applicant: Paul Scherrer InstitutInventors: Martin BEHE, Roger SCHIBLI
-
Publication number: 20210145991Abstract: An apparatus for sterilizing objects includes a chamber with a heated base in thermal communication with an electric heating element ; a forced air flow device arranged to direct air into the chamber; an electrical power supply circuit; a thermomechanical control in series with the electric heating element and arranged to detect a temperature of the heated base; and a thermally sensitive switch in series with the forced air flow device and arranged to detect a temperature of the heated base. The apparatus is configured to operate in a sterilization mode and in a drying mode.Type: ApplicationFiled: December 6, 2018Publication date: May 20, 2021Inventor: Colin Peter Moughton
-
Publication number: 20210145992Abstract: A medical sterilizer for sterilizing a dental handpiece is disclosed. The medical sterilizer according to an embodiment of the present invention comprises: a transparent case made of a transparent material through which the interior can be seen and constitutes a part of the body; an opaque case formed by extending upwards of the transparent case, having a light source inside the upper end that radiates ultraviolet rays and is made of opaque material that does not allow the ultraviolet rays radiating from the above light source to pass through: a rubber stopper formed below the transparent case and containing a hole in which the dental handpiece can be inserted; and a lower portion fixing cap securing the rubber stopper to the opaque case.Type: ApplicationFiled: December 2, 2019Publication date: May 20, 2021Applicant: CARELIVE CO., LTD.Inventor: Hyun Sook KIM
-
Publication number: 20210145993Abstract: Container treatment plant for treating containers, such as bottles, in the beverage processing industry comprising a chlorine dioxide producer, a chlorine dioxide consumer, comprising at least one container treatment machine, in particular a pasteurizer, such as a tunnel pasteurizer, and a metering device that can introduce a solution containing chlorine dioxide produced in the chlorine dioxide producer into the chlorine dioxide consumer, where the chlorine dioxide producer is configured to produce chlorine dioxide through a reaction of sodium chlorite and sulfuric acid.Type: ApplicationFiled: March 14, 2019Publication date: May 20, 2021Inventors: Tim HUFENBACH, Jan MUENZER, Bernhard UNRECHT, Merret SACHT
-
Publication number: 20210145994Abstract: An apparatus for destroying pathogens includes a platform and an LED matrix panel. The platform has a portion configured to permit passage of ultraviolet light therethrough. The LED matrix panel is disposed below the portion of the platform and includes a grid and a plurality of discreetly-controlled, ultraviolet light LEDs (UV LEDs). The grid defines a plurality of cells. Each UV LED is associated with one cell such that the cells direct the ultraviolet light emitted by the UV LEDs upwardly through the portion of the platform to sanitize an object supported on the portion of the platform.Type: ApplicationFiled: January 26, 2021Publication date: May 20, 2021Inventors: Rachel Dombrowsky, Christopher Montalbano, Andrew Martin, Philip Beamer
-
Publication number: 20210145995Abstract: A sanitization system for an amusement park includes a sanitizing source for sanitizing a ride vehicle. The sanitization system may include a controller that receives an indication that the ride vehicle is in a position for sanitization. The sanitization system may include a sanitizing source, which the controller may lower into position to sanitize the ride vehicle. When sanitization is complete, the controller may raise the sanitizing source out of position. The controller may then send an indication that the ride vehicle is sanitized.Type: ApplicationFiled: January 26, 2021Publication date: May 20, 2021Inventor: David Majdali
-
Publication number: 20210145996Abstract: Screening systems and methods for inspecting and sterilizing objects include a scanner with an upstream side having an entry shroud and a downstream side having an exit shroud. The scanner houses an inspection volume coupled to a radiation source and a detector array. Ultra-violet light curtains are positioned at the entry shroud and a first conveyor transports objects through the ultra-violet light curtains and into the inspection volume for scanning. A second conveyor transports the objects from the inspection volume after scanning.Type: ApplicationFiled: November 14, 2020Publication date: May 20, 2021Inventors: Edward James Morton, Magesh Raman Ramakrishnan, Adrian Michael Kelly, Jeremy Charles Norton
-
Publication number: 20210145997Abstract: Method of calculating an exposure time for disinfecting a room using an ultraviolet disinfecting apparatus comprises the steps of measuring distances by: using a spatial sensor on the ultraviolet disinfecting apparatus, to perform a first scan of a boundary surface of the room, to measure a first set of distances from the sensor to the boundary surface; adjusting the height or orientation of the spatial sensor; using the spatial sensor to perform a second scan of the boundary surface of the room, to measure a second set of distances from the adjusted sensor to the boundary surface; and subsequently, calculating the exposure time in dependence the sets of distances.Type: ApplicationFiled: January 26, 2021Publication date: May 20, 2021Inventor: Adam FUDAKOWSKI
-
Publication number: 20210145998Abstract: The invention relates to malodor masking compositions and/or ingredients, methods for counteracting or masking malodors, and perfuming compositions having odor masking properties comprising 2, 4-dialkyl substituted pyridines for formula (I).Type: ApplicationFiled: July 5, 2018Publication date: May 20, 2021Inventors: Monica Bandera, Sanja Fitzgerald, Yang Huang, Matthew Rogers, Ben Smith